Third Harmonic Bio Inc
THRD5.380USD
0.000
Close 12/22, 16:00（ET）Quotes delayed by 15 min
241.86MMarket Cap
LossP/E TTM
More Details of Third Harmonic Bio Inc Company
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Third Harmonic Bio Inc Info
Ticker SymbolTHRD
Company nameThird Harmonic Bio Inc
IPO dateSep 15, 2022
CEO- -
Number of employees53
Security typeOrdinary Share
Fiscal year-endSep 15
Address1700 Montgomery Street
CitySAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94111
Phone12097272457
Websitehttps://thirdharmonicbio.com/
Ticker SymbolTHRD
IPO dateSep 15, 2022
CEO- -
Company Executives of Third Harmonic Bio Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Christopher M. Murphy
Mr. Christopher M. Murphy
Chief Financial and Business Officer and Principal financial officer
Chief Financial and Business Officer and Principal financial officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Gladstone
Mr. Michael Gladstone
Independent Director
Independent Director
--
--
Mr. Thomas M. Soloway
Mr. Thomas M. Soloway
Independent Director
Independent Director
--
--
Dr. H. Martin Seidel, Ph.D.
Dr. H. Martin Seidel, Ph.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Geoff Mcdonough, M.D.
Dr. Geoff Mcdonough, M.D.
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
Other
43.30%
Shareholders
Shareholders
Proportion
Atlas Venture
23.05%
OrbiMed Advisors, LLC
12.81%
BML Capital Management LLC
8.47%
Nantahala Capital Management, LLC
6.51%
Novartis AG
5.86%
Other
43.30%
Shareholder Types
Shareholders
Proportion
Investment Advisor
9.44%
Corporation
5.86%
Investment Advisor/Hedge Fund
0.32%
Individual Investor
0.28%
Other
84.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
211
40.29M
89.28%
-16.85M
2025Q1
212
42.91M
95.09%
-14.37M
2024Q4
195
49.11M
108.99%
-3.57M
2024Q3
188
48.20M
116.40%
-5.90M
2024Q2
179
44.41M
107.54%
-7.00M
2024Q1
168
42.07M
102.65%
-7.97M
2023Q4
157
42.10M
104.28%
-7.14M
2023Q3
134
41.90M
103.75%
-2.52M
2023Q2
124
40.16M
99.46%
-3.19M
2023Q1
118
40.99M
101.62%
+118.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Atlas Venture
--
0%
--
--
OrbiMed Advisors, LLC
--
0%
--
--
BML Capital Management LLC
--
0%
--
--
Nantahala Capital Management, LLC
--
0%
--
--
Novartis AG
--
0%
--
--
TCG Crossover Management, LLC
--
0%
-590.00K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
+221.82K
-100.00%
The Vanguard Group, Inc.
--
0%
+138.49K
-100.00%
D. E. Shaw & Co., L.P.
--
0%
+677.35K
-100.00%
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Avantis US Small Cap Equity ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Biotechnology ETF
0.01%
View more
iShares Micro-Cap ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Third Harmonic Bio Inc?
The top five shareholders of Third Harmonic Bio Inc are:
Atlas Venture holds 0.00 shares, accounting for 0.00% of the total shares.
OrbiMed Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BML Capital Management LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Nantahala Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Novartis AG holds 0.00 shares, accounting for 0.00% of the total shares.
Atlas Venture holds 0.00 shares, accounting for 0.00% of the total shares.
OrbiMed Advisors, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
BML Capital Management LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Nantahala Capital Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Novartis AG holds 0.00 shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Third Harmonic Bio Inc?
The top three shareholder types of Third Harmonic Bio Inc are:
Atlas Venture
OrbiMed Advisors, LLC
BML Capital Management LLC
Atlas Venture
OrbiMed Advisors, LLC
BML Capital Management LLC
How many institutions hold shares of Third Harmonic Bio Inc (THRD)?
As of 2025Q2, 211 institutions hold shares of Third Harmonic Bio Inc, with a combined market value of approximately 40.29M, accounting for 89.28% of the total shares. Compared to 2025Q1, institutional shareholding has increased by -5.82%.
What is the biggest source of revenue for Third Harmonic Bio Inc?
In --, the -- business generated the highest revenue for Third Harmonic Bio Inc, amounting to -- and accounting for --% of total revenue.
